Apolipoprotein AI and alcoholic liver disease

Area of Science:

• Biochemistry
• Hepatology
• Clinical Diagnostics

Background:

• Alcoholic liver disease (ALD) encompasses a spectrum of conditions.
• Apolipoprotein AI (ApoAI) is a major component of high-density lipoprotein (HDL).
• Changes in ApoAI may reflect liver injury severity in ALD.

Purpose of the Study:

• To investigate ApoAI changes across ALD stages.
• To correlate ApoAI levels with liver function tests.
• To assess ApoAI's diagnostic and prognostic utility in ALD.

Main Methods:

• Prospective study of 581 alcoholic patients and 100 controls.
• Measurement of serum ApoAI concentrations.
• Correlation with liver disease staging (steatosis, fibrosis, cirrhosis).
• Analysis of diagnostic and prognostic value.

Main Results:

• ApoAI levels inversely correlate with liver injury severity: highest in steatosis, lowest in cirrhosis.
• ApoAI independently discriminates between steatosis and fibrosis (p<0.001).
• ApoAI differentiates cirrhosis from non-cirrhotic fibrosis and acute hepatitis (p<0.001).
• Low ApoAI (<100 mg/dL) in cirrhosis predicted lower 1-year survival, but this was not independent.

Conclusions:

• Serum ApoAI levels reflect the degree of liver damage in alcoholic liver disease.
• ApoAI demonstrates significant diagnostic value for staging ALD.
• While indicative of poorer prognosis in cirrhosis, its independent prognostic value is limited by other factors.